Welcome to our dedicated page for Psyence Biomedical Ltd. news (Ticker: PBM), a resource for investors and traders seeking the latest updates and insights on Psyence Biomedical Ltd. stock.
Psyence Biomedical Ltd. (PBM) pioneers natural psilocybin therapies for mental health challenges in palliative care through rigorous clinical research. This dedicated news hub provides investors and medical professionals with essential updates on therapeutic developments shaping the future of psychedelic medicine.
Access real-time announcements about clinical trial milestones, manufacturing advancements, and strategic partnerships. Our curated collection includes press releases covering regulatory progress, research publications, and operational updates from the company’s EU GMP-compliant production facility.
Key content categories include phase trial results for Adjustment Disorder therapies, psilocybin cultivation innovations, and collaborative research initiatives with leading clinical organizations. All materials maintain strict compliance with pharmaceutical disclosure standards and financial reporting requirements.
Bookmark this page for direct access to Psyence Biomedical’s verified announcements. Stay informed about groundbreaking developments in psychedelic-assisted psychotherapy and evidence-based treatment protocols through our comprehensive news repository.
Psyence Biomedical (Nasdaq: PBM) has entered into a $25 million common stock purchase agreement with White Lion Capital, This 24-month agreement allows Psyence Biomed to sell up to $25 million in shares to White Lion, subject to certain conditions. The purchase price will be 90% of the lowest VWAP for Fixed Purchase Notices and the lowest traded price for Rapid Purchase Notices. White Lion has agreed not to engage in short selling Psyence Biomed's shares. The agreement can be terminated by Psyence Biomed at any time without penalty.
This funding will support Psyence Biomed's upcoming Phase IIb clinical trial of nature-derived, non-synthetic psilocybin for Adjustment Disorder in Palliative Care, as well as earlier-stage programs in other indications.
Psyence Biomedical (Nasdaq: PBM) has announced the successful export of nature-derived psilocybin to Australia for its upcoming Phase IIb clinical trial. The trial will evaluate psilocybin as a potential treatment for Adjustment Disorder in advanced cancer patients in Palliative Care. The study, supported by partnerships with Fluence and iNGENū, is set to begin shortly.
The randomized, double-blind, placebo-controlled trial will assess two therapeutic doses (10mg, 25mg) against a 1mg active comparator in 84 patients. Psyence Biomed has terminated its commercial licensing agreement with Filament Health but is evaluating new supply agreements. The company remains committed to its development timeline and introducing a novel therapy efficiently.
Psyence Biomedical (Nasdaq: PBM) has received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement. The company’s stock price has remained below $1.00 for 30 consecutive business days, thus failing to meet the criteria set by Nasdaq Listing Rule 5450(a)(1). Psyence has until December 24, 2024, to regain compliance by ensuring its closing bid price hits at least $1.00 for ten consecutive business days. Failure to meet this deadline may result in delisting, though the company can apply for additional time by submitting an online transfer application and paying a $5,000 fee. Options include meeting all other listing standards and potentially implementing a reverse stock split. The notification does not cause immediate delisting, and trading will continue under the symbol 'PBM'.
Psyence Biomedical announced its participation in the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024. The company's management will host one-on-one meetings with investors during the event. This provides an opportunity for investors to engage directly with the company's leadership and gain insights into Psyence Biomed's business strategy and future plans.
FAQ
What is the current stock price of Psyence Biomedical Ltd. (PBM)?
What is the market cap of Psyence Biomedical Ltd. (PBM)?
